Evidence-Based Strategies to Minimize the Likelihood of Axillary Lymph Node Dissection in Clinically Node-Positive Patients Following Neoadjuvant Chemotherapy

Surg Oncol Clin N Am. 2023 Oct;32(4):693-703. doi: 10.1016/j.soc.2023.05.003. Epub 2023 Jun 9.ABSTRACTDe-escalation of axillary management after neoadjuvant chemotherapy in clinically node-positive patients is feasible. The current literature shows this may be accomplished by sentinel lymph node biopsy (SLNB) with the use of dual tracer and removal of at least 2 sentinel lymph nodes, or by targeted axillary dissection (TAD). The accuracy of TAD has been consistently shown as better than that of SLNB. However, these techniques should only be offered to select patients without extensive axillary disease, understanding that long-term outcomes of minimal axillary surgery in this population are limited at this time.PMID:37714637 | DOI:10.1016/j.soc.2023.05.003

Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Ashley A Woodfin Abigail S Caudle Source Type: research